Cargando…

1041. In vitro activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections

BACKGROUND: Tebipenem is under development as an oral treatment option for complicated urinary tract infections and acute pyelonephritis. This study further evaluated the in vitro activity of tebipenem against various fastidious organisms recovered from community-acquired respiratory tract infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arends, S J Ryan, Klauer, Abby L, Cotroneo, Nicole, Critchley, Ian A, Mendes, Rodrigo E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644522/ http://dx.doi.org/10.1093/ofid/ofab466.1235

Ejemplares similares

1038. In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, Against a Collection of Surveillance Gram-Positive Clinical Isolates
por: Arends, S J Ryan, et al.
Publicado: (2021)

1044. In vitro Activity of Tebipenem Against Relevant Clinical Isolates in the Presence of Pulmonary Surfactant
por: Arends, S J Ryan, et al.
Publicado: (2021)

Contemporary Evaluation of Tebipenem In Vitro Activity against Enterobacterales Clinical Isolates Causing Urinary Tract Infections in US Medical Centers (2019–2020)
por: Mendes, Rodrigo E., et al.
Publicado: (2023)

1057. Tebipenem In vitro Activity Against a Collection of Pathogens Responsible for Urinary Tract Infections in the US
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

1695. Tebipenem: An Oral Carbapenem with activity against Multi-drug Resistant Urinary Tract Infection isolates of Escherichia coli collected from US Medical Centers during 2019
por: Critchley, Ian A, et al.
Publicado: (2020)

150. Low Propensity for Development of Spontaneous In Vitro Resistance to Tebipenem, Ertapenem and Meropenem Among Enterobacterales Uropathogens
por: VanScoy, Brian D, et al.
Publicado: (2022)

1254. Molecular Epidemiology of Escherichia coli Causing Urinary Tract Infections in United States and in vitro Activity of Tebipenem, Including Against Strain Lineage and Resistant subsets (2018-2020)
por: Mendes, Rodrigo E, et al.
Publicado: (2021)

1095. Pharmacokinetics-Pharmacodynamics Evaluation of Tebipenem Pivoxil Hydrobromide Using the 10-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2021)

1281. An Evaluation of Tebipenem In Vitro Activity Against a Panel of Pseudomonas aeruginosa Isolates with Efflux, AmpC, and OprD Mutations
por: VanScoy, Brian D, et al.
Publicado: (2021)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017
por: Critchley, Ian A., et al.
Publicado: (2019)

Fastidious Operating
Publicado: (1888)

1565. Characterization of Tebipenem (SPR859) Pharmacokinetics–Pharmacodynamics (PK-PD) for Efficacy Against Enterobacteriaceae in a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2019)

1105. Population Pharmacokinetic Analyses for Tebipenem After the Administration of Tebipenem Pivoxil Hydrobromide
por: Ganesan, Harish, et al.
Publicado: (2021)

1465. Resistance to Oral Antibiotics Among Urinary Tract Infection Isolates of Escherichia coli from the United States and Europe in 2017
por: Critchley, Ian A, et al.
Publicado: (2019)

Crystal structure of tebipenem pivoxil
por: Tang, Chao, et al.
Publicado: (2018)

Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide
por: Ganesan, H., et al.
Publicado: (2023)

1113. Oral Tebipenem as Step-Down Therapy Following Intravenous Ertapenem in a 7-day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2021)

The CURE for Cultivating Fastidious Microbes
por: Bakshi, Arundhati, et al.
Publicado: (2019)

β-Cyclodextrin 10.41-hydrate
por: Seidel, Rüdiger W., et al.
Publicado: (2009)

Fungal Planet description sheets: 951–1041
por: Crous, P.W., et al.
Publicado: (2019)

Environmental and occupational respiratory diseases – 1041. The evaluation of the role of obesity on adults with bronchial asthma
por: Grzetic-Romcevic, Tanja, et al.
Publicado: (2013)

Unusual Microorganisms. Gram-Negative Fastidious Strains
por: Edberg, Stephen C.
Publicado: (1984)

2159. Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in the United States in 2022
por: Arends, S J Ryan, et al.
Publicado: (2023)

1041. Tenofovir alafenamide associated weight change in persons living with HIV
por: Crowder, Carlysle E, et al.
Publicado: (2020)

1062. Analysis of Resistance to Oral Standard of Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected Worldwide between 2019-2020
por: Arends, S J Ryan, et al.
Publicado: (2021)

Evidence of gene nucleotide composition favoring replication and growth in a fastidious plant pathogen
por: Castillo, Andreina I, et al.
Publicado: (2021)

Pharmacists and fastidiousness improve compliance with guidelines for stress ulcer prophylaxis
por: Sanders, S, et al.
Publicado: (2012)

1320. In Vitro Activity of Lefamulin against Staphylococcus aureus Isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis
por: Sader, Helio S, et al.
Publicado: (2021)

1041 Economic Burden Associated with Key Gram-negative Pathogens among Patients with Complicated Urinary Tract Infections across US Hospitals
por: Mocarski, Michelle, et al.
Publicado: (2014)

Tebipenem as an oral alternative for the treatment of typhoid caused by XDR Salmonella Typhi
por: Mylona, Elli, et al.
Publicado: (2021)

Bioequivalence of two oral formulations of tebipenem pivoxil hydrobromide in healthy subjects
por: Gupta, Vipul K., et al.
Publicado: (2022)

Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China
por: Su, Yan, et al.
Publicado: (2020)

Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model
por: VanScoy, B. D., et al.
Publicado: (2023)

Detection of Fastidious Vaginal Bacteria in Women with HIV Infection and Bacterial Vaginosis
por: Mitchell, Caroline, et al.
Publicado: (2009)

Lawsonia intracellularis: Revisiting the Disease Ecology and Control of This Fastidious Pathogen in Pigs
por: Karuppannan, Anbu K., et al.
Publicado: (2018)

Improving sensitivity of single tube nested PCR to detect fastidious microorganisms
por: Shatleh-Rantisi, Diala, et al.
Publicado: (2020)

Genome-Scale Investigation of the Metabolic Determinants Generating Bacterial Fastidious Growth
por: Gerlin, Léo, et al.
Publicado: (2020)

Detection and Identification by Immune Electron Microscopy of Fastidious Agents Associated with Respiratory Illness, Acute Nonbacterial Gastroenteritis, and Hepatitis A
por: Kapikian, Albert Z., et al.
Publicado: (1975)

Stress Degradation Studies of Tebipenem and a Validated Stability-Indicating LC Method
por: Cielecka-Piontek, Judyta, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2mfd5kk98jcdvu1174kqqvnvrg